NYSE:AMPE Ampio Pharmaceuticals (AMPE) Stock Price, News & Analysis $0.18 0.00 (0.00%) As of 10/2/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Ampio Pharmaceuticals Stock (NYSE:AMPE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ampio Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.18▼$0.1850-Day Range$0.18▼$0.1852-Week Range$0.00▼$0.64VolumeN/AAverage Volume2,326 shsMarket Capitalization$207.82 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ampio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and degenerative diseases. The company’s primary area of interest has been osteoarthritis of the knee, a condition characterized by cartilage breakdown, pain and inflammation. Ampio’s lead investigational product has been Ampion, an intra-articular injection designed to provide anti-inflammatory effects in the knee. The product has been evaluated in clinical studies involving patients with osteoarthritis, including individuals with severe disease. Ampion is an investigational therapy and has not been established as an approved commercial treatment. Based in Englewood, Colorado, Ampio has conducted its research and clinical-development activities primarily in the United States. The company has historically focused its resources on advancing Ampion through regulatory and clinical evaluation rather than marketing an established portfolio of pharmaceutical products. Information about its current leadership and development pipeline may change as the company’s clinical strategy evolves.AI Generated. May Contain Errors. Read More Receive AMPE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMPE Stock News HeadlinesAMPE Ampio Pharmaceuticals, Inc.June 13, 2025 | seekingalpha.comAmpio Announces Notice of Proposed Settlement of Stockholder Derivative Actions and Settlement HearingJanuary 30, 2025 | markets.businessinsider.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 4 at 1:00 AM | Altimetry (Ad)Ampio Pharmaceuticals (OTC:AMPE) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comAmpio Pharmaceuticals, Inc. (AMPE)May 17, 2024 | finance.yahoo.comAmpio Pharmaceuticals, Inc.: Ampio Provides Update on Results from Pre-IND Enabling StudiesFebruary 15, 2024 | finanznachrichten.deAmpio Pharmaceuticals Announces At-The-Market Stock OfferingJanuary 26, 2024 | msn.comSociedad Quimica Y Minera de Chile, Altice USA, Cingulate among premarket gainers' packDecember 28, 2023 | seekingalpha.comSee More Headlines AMPE Stock Analysis - Frequently Asked Questions How have AMPE shares performed this year? Ampio Pharmaceuticals' stock was trading at $0.0052 at the beginning of 2026. Since then, AMPE stock has increased by 3,421.2% and is now trading at $0.1831. How were Ampio Pharmaceuticals' earnings last quarter? Ampio Pharmaceuticals, Inc. (NYSE:AMPE) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.40) earnings per share for the quarter, meeting the consensus estimate of ($0.40). When did Ampio Pharmaceuticals' stock split? Shares of Ampio Pharmaceuticals reverse split on the morning of Tuesday, September 12th 2023.The 1-20 reverse split was announced on Thursday, August 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Ampio Pharmaceuticals? Shares of AMPE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ampio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ampio Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Trevena (TRVN), GE Aerospace (GE) and Catalyst Pharmaceuticals (CPRX). Company Calendar Last Earnings11/10/2021Today10/04/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:AMPE CIK1411906 Webampiopharma.com Phone720-437-6500Fax720-437-6501Employees6Year Founded2010Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.05Miscellaneous Outstanding Shares1,135,000Free Float1,098,000Market Cap$207.82 thousand OptionableNo Data Beta5.96 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSE:AMPE) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredFree Stock: Economist calls it “the world’s most important machine.”Nvidia's most expensive chip component isn't made by Nvidia. Jeff Brown, former semiconductor executive, says ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ampio Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
